Equity Details
Price & Market Data
Price: $3.17
Daily Change: $0.00 / 0.00%
Daily Range: $3.04 - $3.20
Market Cap: $350,498,112
Daily Volume: 2,314,816
Performance Metrics
1 Week: 6.73%
1 Month: 14.86%
3 Months: 72.28%
6 Months: 35.47%
1 Year: 100.6%
YTD: 65.97%
About C4 Therapeutics, Inc. (CCCC)
Detailed report on C4 Therapeutics, Inc. (CCCC). Current price: 3.17, daily change: $0.00 / 0.00%. Market cap: 350,498,112. Explore all performance metrics.
Company Details
Employees: 104
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.